...
首页> 外文期刊>The Journal of Antimicrobial Chemotherapy >In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide.
【24h】

In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide.

机译:喹喔啉1,4-二-N-氧化物的酮和酰胺衍生物的体外和体内抗分枝杆菌活性。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: To evaluate a novel series of quinoxaline 1,4-di-N-oxides for in vitro activity against Mycobacterium tuberculosis and for efficacy in a mouse model of tuberculosis (TB). METHODS: Ketone and amide derivatives of quinoxaline 1,4-di-N-oxide were evaluated in in vitro and in vivo tests including: (i) activity against M. tuberculosis resistant to currently used antitubercular drugs including multidrug-resistant strains (MDR-TB resistant to isoniazid and rifampicin); (ii) activity against non-replicating persistent (NRP) bacteria; (iii) MBC; (iv) maximum tolerated dose, oral bioavailability and in vivo efficacy in mice; and (v) potential for cross-resistance with another bioreduced drug, PA-824. RESULTS: Ten compounds were tested on single drug-resistant M. tuberculosis. In general, all compounds were active with ratios of MICs against resistant and non-resistant strains of
机译:目的:评价一系列新的喹喔啉1,4-二-N-氧化物系列在体外抗结核分枝杆菌的活性以及在小鼠结核病(TB)模型中的功效。方法:在体外和体内试验中评估了喹喔啉1,4-二-N-氧化物的酮和酰胺衍生物,包括:(i)对结核分枝杆菌的耐药性,对目前使用的抗结核药物(包括耐多药菌株)具有抗药性耐异烟肼和利福平的结核病); (ii)对非复制型持久性(NRP)细菌的活性; (iii)MBC; (iv)小鼠的最大耐受剂量,口服生物利用度和体内功效; (v)与另一种生物还原药物PA-824交叉耐药的潜力。结果:在单一耐药结核分枝杆菌上测试了十种化合物。一般而言,所有化合物均具有MIC的抗药性和非抗药性菌株≤4.00的活性。一种化合物5在TB的鼠模型中具有口服活性,具有杀菌作用,对NRP细菌具有活性,对MDR-TB和对多药耐药的临床分离株(对3-5种抗结核药有耐药性)具有活性。结论:喹喔啉1,4-二-N-氧化物代表了一类新型的口服抗结核药物。它们可能被生物还原为活性代谢物,但细菌活化的途径不同于临床试验中可生物还原的硝基咪唑PA-824。化合物5具有杀菌作用,并且对NRP生物具有活性,表明活化发生在生长和非复制细菌中,导致细胞死亡。 NRP细菌的存在被认为是导致抗结核治疗的延长性质的主要因素。如果杀菌活性和体外对非复制细菌的活性转化为体内条件,喹喔啉1,4-二-N-氧化物可能会提供缩短治疗的途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号